4) Since the introduction of dideoxynucleoside
reverse transcriptase inhibitors (NRTIs) in 1985 and after the approval of the first protease inhibitor in 1995, the availability of new fixed-dose combinations regimens of new antiretroviral drugs, evolved faster in the developed world.
The PC12 cell as a model for studies of the mechanism of inducing of peripheral neuropathy by anti-HIV-l dideoxynucleoside
In vitro models to predict the in vivo mechanism, rate and extet of placental transfer of dideoxynucleoside
drugs against human immunodeficiency virus.
Lamivudine (3TC), the negative enantiomer of 2'-deoxy-3'thiacytidine, is a dideoxynucleoside
analogue used in combination with other agents in the treatment of human immunodeficiency virus type 1 (HIV-1) infection and as monotherapy in the treatment of hepatitis B virus (HBV) infection.
Assay-specific deoxynucleoside triphosphates (dATP, dGTP, dTTP; Amersham) and dideoxynucleoside
triphosphates (ddA, ddC, ddG, ddT; BioLog Life Science Institute) were added at 0.
Therefore, in that study, a very short extension strategy using alternating deoxynucleoside triphosphates (dNTPs) and dideoxynucleoside triphosphates was adopted so that the products differed in mass by [M.
75 [micro]M primer, 25 [micro]M each of the dideoxynucleoside triphosphates (Amersham Pharmacia Biotech), and 0.
Our strategy for detecting the splice variants expressed from the genes is based on the extension of gene-specific minisequencing primers with fluorescent dideoxynucleoside triphosphates (ddNTPs), each of which define a specific splice variant (see Table 52 in the online Data Supplement).
1) Nonstandard abbreviations: HAEC, human aortic endothelial cell; HUVEC, human umbIIical vein endothelial cell; dNTP, deoxynucleoside triphosphate; ddNTP, dideoxynucleoside triphosphate; Ct, threshold cycle; s/n, signal-to-noise rafio; and s/i, signal iracfion.
DNA polymerase extends it by adding one fluorescently labeled dideoxynucleoside
triphosphate complementary to the variant base.
Emergence of human immunodeficiency virus type 1 variants with resistance to multiple dideoxynucleosides
in patients receiving therapy with dideoxynucleosides
Comparison of mitochondrial morphology, mitochondrial DNA content, and cell viability in cultured cells treated with three anti-human immunodeficiency virus dideoxynucleosides